



## **GNI and Organon Extend and Expand Collaborative Research**

**Tokyo, March 31, 2008** – GNI Ltd, a leading biopharmaceutical company in Japan and China, and Organon, a part of Schering-Plough, today announced an agreement to extend and expand the collaborative research program that they started in 2006. The new efforts, aimed at both understanding the protein structures and establishing nuclear hormone receptor assays, will last for 12-18 months. The program will be carried out by scientists at Shanghai Genomics, GNI's main research facility, which is located in China.

Dr. Jun Wu, Chief Scientific Officer of GNI, said, "With fast globalization of drug discovery, multi-national pharmaceutical companies are increasingly looking for partners in Asian countries, such as China and India. Collaboration with multi-nationals has been a major part of our R&D strategy. We are very pleased that Organon recognizes our research strengths and has decided to extend and expand our previous collaboration."

GNI and Shanghai Genomics combined in 2005. Since then, the company has been focusing on leveraging its cost-effectiveness in China to develop novel therapeutic agents for pulmonary and liver diseases. The company's drug target discovery program has resulted in multiple research publications and granted patents. In addition to its internal drug discovery programs, Shanghai Genomics has also established research collaborations with international pharmaceutical companies.

### **For further inquiries:**

Ken Suzuki    Tel: +81 (03) 3580-0751  
Ying Luo      Tel: +86 1381-769-8961

### **About GNI**

Founded in 2001, GNI, Ltd. is a clinical-stage international drug development company with its headquarters in Tokyo, Japan, and major operations in Shanghai, China. In June 2005, GNI acquired Shanghai Genomics, which was also founded in 2001, and currently operates an integrated drug discovery and development platform in Shanghai. The combined strengths of GNI and Shanghai Genomics has resulted in research collaborations with major international pharmaceutical companies. GNI has offices in Beijing, Tianjin, and Zhengzhou, China and Fukuoka, Japan. For further information, please visit [www.gnipharma.com](http://www.gnipharma.com) and [www.shanghai-genomics.com](http://www.shanghai-genomics.com).

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "could," "may," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. GNI does not undertake any obligation to update forward-looking statements.